A detailed history of Farther Finance Advisors, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 260 shares of MYGN stock, worth $6,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260
Previous 214 21.5%
Holding current value
$6,359
Previous $4.96 Million 12.36%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$17.59 - $23.59 $809 - $1,085
46 Added 21.5%
260 $5.57 Million
Q4 2023

Feb 14, 2024

BUY
$13.91 - $21.32 $264 - $405
19 Added 126.67%
34 $651,000
Q3 2023

Nov 13, 2023

SELL
$15.99 - $23.22 $3,182 - $4,620
-199 Reduced 92.99%
15 $241,000
Q1 2023

May 13, 2024

BUY
$15.26 - $23.75 $2,746 - $4,275
180 Added 529.41%
214 $4.97 Million
Q1 2023

Sep 12, 2023

BUY
$15.26 - $23.75 $3,036 - $4,726
199 Added 1326.67%
214 $4.97 Million
Q4 2022

Sep 11, 2023

BUY
$14.51 - $20.99 $217 - $314
15 New
15 $218,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.97B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.